NanoBio^® Protect is an over-the-counter alcohol-free nasal antiseptic solution that can be used to help reduce germs on skin that could cause infections, including respiratory infection. The product is applied by thoroughly swabbing the skin inside of each nostril. The effectiveness of NanoBio Protect is derived from BlueWillow’s patented nanotechnology platform that enables long-lasting effectiveness to disrupt germs residing on the skin’s surface.

BlueWillow Biologics^® is a clinical-stage, privately-held biopharmaceutical company focused on developing and commercializing topical antiseptic and anti-infective products and intranasal vaccines using its patented nanotechnology platform. The platform employs novel oil-in-water nano-droplets for products administered to the skin and nose.

In addition to the company’s lead NanoBio^® Protect product, BlueWillow Biologics is developing its proprietary NanoVax^® platform to enable intranasal vaccines for challenging respiratory & sexually transmitted infections and intranasal immunotherapy (INIT) for food & respiratory allergies. The company’s lead candidates include intranasal vaccines for influenza, anthrax, RSV and HSV-2, and intranasal immunotherapy for peanut and milk allergy. The company’s NanoVax^® technology platform utilizes a novel oil-in-water emulsion adjuvant to enable intranasal vaccines and immunotherapy that elicit mucosal and systemic Th1/Th17 immunity. The NanoVax^® platform uniquely elicits mucosal antibodies that serve as “bouncers at the door” as the body’s first line of defense against infections and allergens.